Pirtobrutinib combo for BTK-treated DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of targeted drugs for people with a type of lymphoma (DLBCL) that has come back or not responded after previous treatment with a BTK inhibitor. The goal is to see if adding a drug called pirtobrutinib to standard chemotherapy helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific subtype of diffuse large B-cell lymphoma (DLBCL) that is known to respond to BTK inhibitors.
- Your lymphoma has gotten worse or come back after treatment with a BTK inhibitor (like ibrutinib, acalabrutinib, or zanubrutinib).
- You have at least one tumor that can be measured on a PET/CT scan (for example, a lymph node larger than about half an inch).
- You are generally well enough to be up and about (ECOG score 0-2) and over 18 years old.
- Your heart, liver, kidneys, and blood counts are working well enough to handle the treatment.
- You are not pregnant and you agree to use effective birth control during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a combination of three targeted drugs (polatuzumab vedotin, zanubrutinib, and R-CHP) for people newly diagnosed with a specific subtype of DLBCL called non-GCB. The goal is to see if this powerful mix can work better than standard treatment.
This trial tests a combination of targeted antibody drugs (polatuzumab vedotin and rituximab) plus two chemo drugs (gemcitabine and oxaliplatin) for people with DLBCL whose cancer returned after their first treatment and who cannot have a stem cell transplant. The goal is to see if this combination works better as a second-line treatment.
This trial tests a new targeted therapy (pirtobrutinib) added to standard chemotherapy for a specific type of lymphoma. It aims to see if the combination improves outcomes for patients who have not been treated before.
This trial tests a new combination of drugs for a certain type of lymphoma (non-GCB DLBCL). The drugs are pirtobrutinib (a targeted pill) plus a standard chemotherapy regimen called Pola-R-CHP. The goal is to see if adding this targeted therapy improves outcomes for people with this specific subtype.
This trial tests a new drug called pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is for those whose cancer has come back or not responded to treatment, including a prior BTK inhibitor, and also for those who have never been treated but have a specific genetic change (17p deletion).
Hear when a new Relapsed and Refractory DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.